NZ591488A - Anti-extended type i glycosphingolipid antibody, derivatives thereof and use - Google Patents

Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Info

Publication number
NZ591488A
NZ591488A NZ591488A NZ59148808A NZ591488A NZ 591488 A NZ591488 A NZ 591488A NZ 591488 A NZ591488 A NZ 591488A NZ 59148808 A NZ59148808 A NZ 59148808A NZ 591488 A NZ591488 A NZ 591488A
Authority
NZ
New Zealand
Prior art keywords
antibody
extended type
derivatives
epitope
seq
Prior art date
Application number
NZ591488A
Inventor
Tong-Hsuan Chang
Jerry Ting
Tsai-Hsia Hong
Mei-Chun Yang
Liahng-Yirn Liu
Shu-Yen Chang
Ying-Zin Chen
Jaw-Yuan Wen
Kazuko Handa
Sen-Itiroh Hakomori
Original Assignee
Glyconex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glyconex Inc filed Critical Glyconex Inc
Priority to NZ591488A priority Critical patent/NZ591488A/en
Publication of NZ591488A publication Critical patent/NZ591488A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Abstract

Disclosed is a human monoclonal antibody or antigen binding portion thereof that specifically binds an epitope comprising an extended Type I chain comprising Leb, wherein said epitope is expressed on a cancer cell, wherein said antibody or antigen binding portion thereof does not bind to Ley , and wherein the antibody has a heavy chain variable region having the amino acid sequence that has 80%-100% identity with SEQ ID NO 15, and a light chain variable region having the amino acid sequence that has 80%-100% identity with SEQ ID NO 17.
NZ591488A 2008-09-07 2008-09-07 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use NZ591488A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ591488A NZ591488A (en) 2008-09-07 2008-09-07 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ591488A NZ591488A (en) 2008-09-07 2008-09-07 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
PCT/US2008/075533 WO2010027364A1 (en) 2008-09-07 2008-09-07 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Publications (1)

Publication Number Publication Date
NZ591488A true NZ591488A (en) 2012-11-30

Family

ID=41797355

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591488A NZ591488A (en) 2008-09-07 2008-09-07 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Country Status (18)

Country Link
US (1) US8163497B2 (en)
EP (1) EP2324060B1 (en)
JP (1) JP5611210B2 (en)
KR (2) KR101442323B1 (en)
CN (1) CN102282172B (en)
AU (1) AU2008361352B2 (en)
BR (1) BRPI0823049A2 (en)
CA (1) CA2735433C (en)
DK (1) DK2324060T3 (en)
ES (1) ES2549877T3 (en)
HK (1) HK1157363A1 (en)
IL (1) IL211561A (en)
MX (1) MX2011002478A (en)
NZ (1) NZ591488A (en)
RU (1) RU2478648C2 (en)
TW (1) TWI433684B (en)
WO (1) WO2010027364A1 (en)
ZA (1) ZA201101547B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703129B2 (en) * 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5168043A (en) 1986-01-10 1992-12-01 Sloan-Kettering Institute For Cancer Research Blood group antigen panel
EP0232706A3 (en) * 1986-01-10 1988-11-30 Sloan-Kettering Institute For Cancer Research Blood group antigen panel
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5011920A (en) 1986-01-30 1991-04-30 Fred Hutchinson Cancer Research Center Disialofucoganglioside immunogen and fucoganglioside monosialosyl Lea II
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE68921364T2 (en) 1988-04-16 1995-06-29 Celltech Ltd Process for the production of proteins using recombinant DNA.
DE68921982T4 (en) 1988-06-14 1996-04-25 Cetus Oncology Corp COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240833A (en) 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6432402B1 (en) * 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Cell culture medium containing insulin or an insulin-like growth factor, transferrin or ferrous ion and triiodothyronine or thyroxin and a method for its use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
JPH06510524A (en) 1991-05-14 1994-11-24 ユニバーシティ オブ コネチカット Targeted delivery of genes encoding immunogenic proteins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0587738T3 (en) 1991-06-05 2000-12-18 Univ Connecticut Destined delivery of genes encoding secretory proteins
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ES2149768T3 (en) 1992-03-25 2000-11-16 Immunogen Inc CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69325777T2 (en) 1992-06-09 2000-03-09 Hoppe Ag LATCH AND DOOR LOCK
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0671923T3 (en) 1992-10-09 2001-08-13 Advanced Tissue Sciences Inc Liver reserve cells
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US5795961A (en) 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
EP1992633A1 (en) 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
EP1276849A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
KR100666238B1 (en) * 2000-07-03 2007-01-09 더 바이오멤브레인 인스티튜트 Extended type 1 chain glycosphingolipids as tumor-associated antigens
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
JP3665316B2 (en) 2001-05-18 2005-06-29 麒麟麦酒株式会社 Anti-TRAIL-R antibody
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity

Also Published As

Publication number Publication date
RU2478648C2 (en) 2013-04-10
US20110142844A1 (en) 2011-06-16
AU2008361352B2 (en) 2013-05-09
JP2012502027A (en) 2012-01-26
US8163497B2 (en) 2012-04-24
IL211561A (en) 2016-04-21
ES2549877T3 (en) 2015-11-02
TWI433684B (en) 2014-04-11
CA2735433C (en) 2016-02-16
BRPI0823049A2 (en) 2015-06-16
DK2324060T3 (en) 2015-10-26
IL211561A0 (en) 2011-05-31
CN102282172B (en) 2014-02-19
RU2011108579A (en) 2012-09-10
KR101432474B1 (en) 2014-08-21
KR20140066785A (en) 2014-06-02
KR20110076912A (en) 2011-07-06
TW201010724A (en) 2010-03-16
KR101442323B1 (en) 2014-09-25
EP2324060B1 (en) 2015-07-22
EP2324060A4 (en) 2011-10-19
CA2735433A1 (en) 2010-03-11
HK1157363A1 (en) 2012-06-29
ZA201101547B (en) 2012-05-30
CN102282172A (en) 2011-12-14
WO2010027364A1 (en) 2010-03-11
MX2011002478A (en) 2011-04-05
JP5611210B2 (en) 2014-10-22
AU2008361352A1 (en) 2010-03-11
EP2324060A1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ621938A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ592215A (en) c-MET ANTIBODIES
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ602220A (en) Antibodies with ph dependent antigen binding
NZ600022A (en) Anti CD37 antibodies
NZ600262A (en) Anti-her3 antibodies and uses thereof
MX2022003718A (en) Antibodies that bind cd39 and uses thereof.
NZ712765A (en) Antibodies that bind csf1r
NZ594682A (en) Fully human antibodies specific to cadm1
NZ616382A (en) Antibodies specific to cadherin-17
WO2015054691A3 (en) Tem8 antibodies and their use
NZ720765A (en) Antibodies and methods of use
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
CY1110895T1 (en) SYNTHETIC AESTHETIC BATTERY AREAS WITH BATTERY PROPERTIES MODIFIED IN THE MORAL AREAS DIFFERENT FROM AREAS
NZ703653A (en) Anti-fap antibodies and methods of use
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ596295A (en) Anti-5T4 antibodies and uses thereof
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ600005A (en) Antibodies against human angiopoietin 2
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
ES2572231T3 (en) Human anti-IL-21 monoclonal antibodies
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GLYCONEX INC., TW

Free format text: OLD OWNER(S): TONG-HSUAN CHANG; JERRY TING; TSAI-HSAI HONG; MEI-CHUN YANG; LIAHNG-YIRN LIU; SHU-YEN CHANG; YING-ZIN CHEN; JAWYUAN WEN; KAZUKO HANDA; SEN-ITIROH HAKOMORI

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO APPLICANT CHAIN OF TITLE (71)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 SEP 2015 BY SOHARE

Effective date: 20130627

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 SEP 2018 BY YU FANG LO

Effective date: 20140829

LAPS Patent lapsed